Clinical Trials Logo

Clinical Trial Summary

This is a randomized controlled study, including dysphagic patients with Parkinson's syndrome who were received in the department of rehabilitation medicine. All patients are randomly allocated to the observation group or the control group. Both groups are provided with comprehensive rehabilitation. Besides, the observation group additionally undergoes the stellate ganglion block. At admission and after 10-day treatment, Functional Oral Intake Scale, Drooling amount, depression are assessed.


Clinical Trial Description

Palliation of dysphagia in patients with Parkinson's syndrome continues to be a challenge. This is a randomized controlled study, including dysphagic patients with Parkinson's syndrome who were received in the department of rehabilitation medicine. All patients are randomly allocated to the observation group or the control group. Both groups are provided with comprehensive rehabilitation. Besides, the observation group additionally undergoes the stellate ganglion block. At admission and after 10-day treatment, Functional Oral Intake Scale, Drooling amount, depression are assessed. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT06370195
Study type Interventional
Source Buraidah Central Hospital
Contact Laviena Ce
Phone 15422548954
Email linchuangzhuce@126.com
Status Not yet recruiting
Phase N/A
Start date April 2024
Completion date December 2024

See also
  Status Clinical Trial Phase
Terminated NCT01950455 - Evaluation of the Diagnostic Efficacy and Safety of [123I]NAV5001 as an Imaging Agent to Aid in the Diagnosis of Parkinsonian Syndromes Phase 3
Completed NCT03667456 - Evaluation of the Uses of a Digital-assisted Self-rehabilitation Device (TELE-PARK) N/A
Completed NCT03638479 - Utilizing Smart Devices to Identify New Phenotypical Characteristics in Movement Disorders
Withdrawn NCT01950468 - A Cross-Over, Multi-Center Trial to Evaluate the Diagnostic Efficacy and Safety of [123I]NAV5001 as an Imaging Agent to Aid in the Diagnosis of Parkinsonian Syndromes Phase 3